GeneDx is trading 4% up at $66.24, extending a multi-session rebound as it tracks a broader tech-led market rally and improved risk sentiment.
- The upward move follows positive macro data and strong earnings from technology peers, despite a lack of fresh company-specific headlines this morning.
- Shares are continuing to recover from recent weakness tied to concerns surrounding Q1 2026 results and subsequent litigation.